TG Therapeutics (TGTX) Reports Q4 Loss of $0.37/Share

TG Therapeutics (NASDAQ: TGTX) reported Q4 EPS of ($0.37), versus ($0.48) reported last year. Revenue for the quarter came in at $38.1 million, versus $38.1 million reported last year.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Morgan Stanley Resumes American Eagle Outfitters (AEO) at Equalweight
• Retail investors largely unaware of SEC semiannual reporting proposal